Successful early treatment combining remdesivir with high‐titer convalescent plasma among COVID‐19‐infected hematological patients

Immunocompromised patients with hematological malignancies are at high risk for a severe course of COVID-19 (Coronavirus Disease 2019) with a deadly outcome.1, 2 With remdesivir use, several randomized trials have recorded abbreviated recovery periods, lower mortality, and positive consequences of early treatment initiation.3, 4 Based on randomized trial results, the FDA has approved remdesivir for the treatment of COVID-19. Regarding...